🇺🇸 beta-1,3-glucan in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Dehydration — 1 report (12.5%)
2. Diarrhoea — 1 report (12.5%)
3. Febrile Neutropenia — 1 report (12.5%)
4. Gastritis — 1 report (12.5%)
5. Hypertension — 1 report (12.5%)
6. Hyponatraemia — 1 report (12.5%)
7. Neutropenia — 1 report (12.5%)
8. Transaminases Increased — 1 report (12.5%)

Source database →

Frequently asked questions

Is beta-1,3-glucan approved in United States?

beta-1,3-glucan does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for beta-1,3-glucan in United States?

Meiji University of Oriental Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.